Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 25;12(9):3126.
doi: 10.3390/jcm12093126.

The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome

Dominika Wróbel-Dudzińska  1 , Agata Przekora  2 , Paulina Kazimierczak  2 , Agnieszka Ćwiklińska-Haszcz  1 , Ewa Kosior-Jarecka  1 , Tomasz Żarnowski  1
Affiliations

The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome

Dominika Wróbel-Dudzińska et al. J Clin Med. .

Abstract

Purpose: The aim of the study was to compare the difference in composition between 100% autologous serum (AS) and 100% platelet-rich plasma (PRP) eye drops and assess their impact on the clinical outcomes after the treatment of severe dry eye (DE) in primary Sjogren Syndrome patients (pSS).

Materials and methods: This is an interventional, non-randomized, comparative, three-month study. 22 patients with severe DE in pSS were treated with 100% AS (22 eyes) and 100% PRP (22 eyes) eye drops 5 times per day in monotherapy mode. The quantifications of growth factors (GFs) such as fibroblast growth factor (FGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), fibronectin, and substance p in hemoderivates were done. The main outcome measures were: Ocular Surface Disease Index (OSDI), Best Corrected Visual Acuity (BCVA), the Schirmer test, tear break-up time (TBUT), corneal and conjunctival staining according to the Oxford scale, conjunctival hyperaemia, and Meibomian gland parameters. The results were compared at baseline, 1 month, and 3 months following the treatment. The clinical results were correlated with the concentration of GFs in the biological tear substitutes.

Results: Significant differences were observed in the concentration of FGF (4.42 ± 0.86 vs. 15.96 ± 7.63, p < 0.0001), EGF (4.98 ± 0.97 vs. 39.06 ± 20.18, p < 0.0001), fibronectin (929.6 ± 111.5 vs. 823.64 ± 98.49, p = 0.0005), VEGF (175.45 ± 65.93 vs. 717.35 ± 488.15, p < 0.0001), PDGF AB (619.6 ± 117.30 vs. 349.66 ± 79.82, p < 0.0001), NGF (85.22 ± 23.49 vs. 8.29 ± 9.06, p < 0.0001), PDGF (935.38 ± 434.26 vs. 126.66 ± 54.41, p < 0.0001), substance p (112.58 ± 27.28 vs. 127.51 ± 26.56, p = 0.0125) in PRP compared to AS. The level of TGF-β was undoubtedly higher in AS than in PRP (1031.37 ± 330.23 vs. 726.03 ± 298.95, p = 0.0004). No significant differences between AS and PRP were observed in the concentration of IGF. Therapy with blood products relieved the signs and symptoms in pSS DE patients. There was a statistically significant improvement in BCVA, the Schirmer test, TBUT, Meibomian gland parameters, and the reduction of the OSDI scores, Oxford staining, and conjunctiva hyperaemia in each of the groups. However, the clinical changes were more significant in the PRP group. There were numerous correlations between the level of GFs and the mean change in clinical outcomes. No adverse events were reported.

Conclusions: Despite the fact that blood derivatives differ in composition, they seem to be effective and safe in the treatment of severe DE in pSS patients. The signs and symptoms of DE were reduced in both groups, but only the mean change in OSDI was statistically significant. A greater reduction in OSDI scores was observed in the PRP group. The obtained results and the composition of haemoderivates may indicate the superiority of PRP in relieving the symptoms of DE in pSS patients compared to AS.

Keywords: autologous serum platelet-rich plasma; dry eye disease; growth factors; primary Sjogren syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Asummary of the design of the study.
See this image and copyright information in PMC

References

    1. Zhan Q., Zhang J., Lin Y., Chen W., Fan X., Zhang D. Pathogenesis and treatment of Sjogren’s syndrome: Review and update. Front. Immunol. 2023;14:1127417. doi: 10.3389/fimmu.2023.1127417. - DOI - PMC - PubMed
    1. Bloch K.J., Buchanan W.W., Wohl M.J., Bunim J.J. Sjoegren’s syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine. 1965;44:187–231. doi: 10.1097/00005792-196505000-00001. - DOI - PubMed
    1. Perella C., Steenackers M., Robbins B., Stone L., Gervais R., Schmidt T., Goswami P. Patient Experience of Sjögren’s Disease and its Multifaceted Impact on Patients’ Lives. Rheumatol. Ther. 2023 doi: 10.1007/s40744-023-00531-7. ahead of print . - DOI - PMC - PubMed
    1. Qin B., Wang J., Yang Z., Yang M., Ma N., Huang F., Zhong R. Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann. Rheum. Dis. 2015;74:1983–1989. doi: 10.1136/annrheumdis-2014-205375. - DOI - PubMed
    1. Bron A.J., de Paiva C.S., Chauhan S.K., Bonini S., Gabison E.E., Jain S., Knop E., Markoulli M., Ogawa Y., Perez V., et al. TFOS DEWS II pathophysiology report. Ocul. Surf. 2017;15:438–510. doi: 10.1016/j.jtos.2017.05.011. Erratum in Ocul. Surf. 2019, 17, 842. - DOI - PubMed